iCAD - ICAD Stock Forecast, Price & News

iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the treatment of cancer in the United States. It operates through two segments, Cancer Detection and Cancer Therapy. The company offers PowerLook platform, which hosts the AI algorithm solutions and manages the communications between imaging acquisition systems, and image storage and review systems; SecondLook, a machine learning-based cancer detection algorithm that analyzes 2D full-field digital mammography images to identify and mark suspicious masses and calcifications; and automated density assessment solutions, which provides automated, consistent, and standardized density assessment. It also offers ProFound AI, a deep-learning algorithm designed to detect malignant soft-tissue densities and calcifications in digital breast tomosynthesis; ProFound AI Risk, a tool that provides breast cancer risk estimation based on a screening mammogram; and magnetic resonance imaging applications, a tool to detect breast and prostate cancer. In addition, the company offers VeraLook, a solution designed to support the detection of colonic polyps in conjunction with CT Colonography. Further, it provides Xoft Axxent electronic brachytherapy systems for the treatment of early stage breast, non-melanoma skin, and gynecological cancers to university research and community hospitals, cancer care clinics, veterinary facilities, and dermatology offices. The company sells its products through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, technology platform partners, and resellers. It also exports its products in Europe, Taiwan, Canada, China, and internationally. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.

Analysts Set New Price Targets

Separately, BTIG Research lowered their price objective on iCAD from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, June 24th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $12.50.

iCAD Stock Performance

Shares of iCAD stock opened at $3.81 on Wednesday. The firm has a market cap of $95.94 million, a PE ratio of -7.19 and a beta of 1.08. iCAD has a 1 year low of $2.91 and a 1 year high of $12.73. The firm's 50-day simple moving average is $4.07 and its 200-day simple moving average is $4.19.

iCAD (NASDAQ:ICAD - Get Rating) last posted its earnings results on Wednesday, May 11th. The technology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.04). iCAD had a negative return on equity of 26.45% and a negative net margin of 40.43%. The firm had revenue of $7.52 million during the quarter, compared to the consensus estimate of $7.50 million. On average, equities analysts predict that iCAD will post -0.57 earnings per share for the current year.